Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
Unlike traditional short-read methods that require days of batch processing, new long-read sequencing technologies like Oxford Nanopore provide real-time data. This allows clinicians to analyze a brain tumor biopsy and determine its specific type in minutes, a process that previously took over a month.
Related Insights
True early cancer detection involves finding microscopic tumor DNA in blood samples. This can identify cancer years before it's visible on an MRI, creating an opportunity for a patient's own immune system to potentially eliminate it before it ever becomes a clinical disease.
Advanced biomarkers are no longer just research tools. Tools like Decipher provide results within a week from a shipped sample, and Artera's MMEI simply requires scanning a pathology slide. This practicality allows clinicians to personalize treatment intensification for high-risk patients in current clinical workflows, moving beyond purely clinical risk factors.
Bypassing complex gene sequencing, a new diagnostic from Asama Health leverages basic physics. It identifies cancerous DNA by measuring changes in electrical resistance caused by altered methylation patterns. This simple, disruptive approach promises a faster, more accessible method for early cancer detection.
Unlike invasive tissue biopsies that sample a single site, liquid blood biopsies provide a comprehensive, real-time snapshot of mutations across all metastatic sites. This is crucial for identifying acquired mutations and guiding timely treatment decisions.
The original Signatera assay used 16 personalized probes based on whole-exome sequencing to find ctDNA. The next-generation version, based on whole-genome sequencing, expands this to 64 probes. This is expected to significantly increase sensitivity, detect molecular relapse earlier, and provide a longer window for clinical intervention.
The NCI-supported MyeloMatch trial is pioneering a new standard for AML diagnostics, providing comprehensive genomic, FISH, and karyotype analysis within 72 hours. This rapid turnaround allows for immediate risk stratification and assignment to appropriate clinical trials.
When an oncologist anticipates an initial sample (e.g., cytology) will likely have insufficient tissue for NGS testing, they proactively initiate a biopsy of a second site with interventional radiology. This parallel-path approach avoids waiting for the first test to fail, significantly reducing time to diagnosis and treatment.
Scaling personalized medicine hinges on converging technologies. Robotics automates lab work from hours to minutes, affordable gene sequencing provides the raw data, and cloud computing processes AI analysis for pennies, making a once-prohibitively expensive process accessible.
Tumor-informed assays like Signatera sequence a patient's tumor to create a personalized test, making it highly sensitive but taking 3-4 weeks. Tumor-uninformed assays are faster (1 week) but less sensitive as they screen for a generic panel of cancer mutations.
Myome and Natera are building foundational models for oncology that function like genomic language models. By training on vast cancer sequence and clinical data, these models learn the context of a patient's disease to predict the next mutation, similar to how transformers like GPT predict the next word in a sentence.
